拟港股上市，“东北药茅”长春高新加码海外市场

Core Viewpoint - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy, accelerate internationalization, and improve overseas financing capabilities [1] Group 1: Financial Performance - In 2024, Changchun High-tech reported a revenue of 13.466 billion yuan, a year-on-year decrease of 7.55% [1] - The net profit attributable to the parent company was 2.583 billion yuan, a significant decline of 43.01% year-on-year [1] - The pharmaceutical sector, which is the core business, generated a revenue of 12.666 billion yuan, accounting for 94.07% of total revenue [1] Group 2: Cost Analysis - R&D expenses increased to 2.690 billion yuan, up 11.20% year-on-year, with R&D costs specifically rising by 25.75% to 2.167 billion yuan due to accelerated new product development and talent acquisition [2] - Sales expenses reached 4.439 billion yuan, an increase of 11.81% year-on-year, aimed at enhancing sales team recruitment and compliance [2] - Management expenses rose to 1.202 billion yuan, a 25.59% increase year-on-year, attributed to adjustments in the management structure of its subsidiary, Jinsai Pharmaceutical [2] Group 3: Subsidiary Performance - Jinsai Pharmaceutical, a key subsidiary, achieved a revenue of 10.671 billion yuan in 2024, a decrease of 3.73% year-on-year, and a net profit of 2.678 billion yuan, down 40.67% year-on-year [2] - The decline in Jinsai Pharmaceutical's performance directly impacted Changchun High-tech's overall financial results [2] Group 4: Strategic Intent - The move to seek a listing in Hong Kong may also be a strategy to alleviate cash flow issues caused by the declining performance of Jinsai Pharmaceutical, aiming to secure new development opportunities through financing [3]